Caprock Group LLC Sells 1,154 Shares of Amgen Inc. (NASDAQ:AMGN)

Caprock Group LLC trimmed its stake in Amgen Inc. (NASDAQ:AMGN) by 7.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,270 shares of the medical research company’s stock after selling 1,154 shares during the period. Caprock Group LLC’s holdings in Amgen were worth $3,980,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in AMGN. Capital Performance Advisors LLP acquired a new stake in shares of Amgen in the third quarter valued at $25,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen in the third quarter worth about $29,000. Matrix Trust Co bought a new stake in shares of Amgen during the third quarter valued at approximately $36,000. Livelsberger Financial Advisory acquired a new stake in shares of Amgen in the third quarter valued at approximately $56,000. Finally, Icon Wealth Advisors LLC raised its position in Amgen by 3,955.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 174,040 shares of the medical research company’s stock worth $56,000 after purchasing an additional 169,748 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.5 %

Amgen stock opened at $285.42 on Friday. The company has a market cap of $153.42 billion, a price-to-earnings ratio of 36.55, a P/E/G ratio of 2.85 and a beta of 0.56. The firm has a 50-day moving average of $271.24 and a 200-day moving average of $304.84. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business’s revenue was up 23.2% compared to the same quarter last year. During the same period last year, the company earned $4.96 earnings per share. On average, equities analysts expect that Amgen Inc. will post 19.56 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.34%. Amgen’s dividend payout ratio (DPR) is currently 115.24%.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Leerink Partners decreased their price target on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Wells Fargo & Company cut their price objective on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a report on Friday, January 10th. Truist Financial lowered their target price on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a report on Wednesday, January 8th. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 price target on shares of Amgen in a research note on Friday, January 24th. Finally, William Blair reaffirmed an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $314.00.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.